Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
- Conditions
- Graft vs. Host Disease
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2020-03-04
- Target Recruit Count
- 54
- Registration Number
- NCT01713400
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
- Conditions
- Chronic Phase Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2021-01-05
- Target Recruit Count
- 11
- Registration Number
- NCT01702064
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
- Conditions
- Metastatic Melanoma
- Interventions
- Procedure: Tumor Infiltrating Lymphocytes (TIL)Drug: Administration of LymphodepletionBiological: Adoptive Cell Therapy with TIL
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 13
- Registration Number
- NCT01701674
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2016-03-04
- Target Recruit Count
- 13
- Registration Number
- NCT01683149
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2022-10-06
- Target Recruit Count
- 44
- Registration Number
- NCT01680965
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Mayo Clinic Cancer Center, Phoenix, Arizona, United States
Evaluating Biobanking Educational Tools
- Conditions
- Neoplasm
- Interventions
- Other: TBCCN-developed educational materialsOther: NCI-developed educational materials
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2021-09-21
- Target Recruit Count
- 339
- Registration Number
- NCT01672944
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Procedure: Endoscopic Ultrasound (EUS)
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2022-10-07
- Target Recruit Count
- 90
- Registration Number
- NCT01662609
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Lehigh Valley Health Network, Allentown, Pennsylvania, United States
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- Procedure: ACT with TIL InfusionDrug: Lymphodepletion
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 17
- Registration Number
- NCT01659151
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2023-01-19
- Target Recruit Count
- 21
- Registration Number
- NCT01657591
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States